The US Food and Drug Administration wants to hear from the medical device industry on how to regulate 3D-printed manufactured devices at point-of-care (POC) settings. Based on the feedback, it plans to develop a risk-based guidance that is not too burdensome.
It may sound like science fiction, but the future of medical devices as envisioned by many is a future where clinicians are able to 3D print devices at POC locations such as clinics and hospitals to provide personalized care. But that future also leaves regulators with a massive headache over how to oversee good manufacturing practices (GMP) of such devices
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?